LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• LifeStance Health Group, Inc. has received a consensus rating of "Moderate Buy" from analysts, with an average twelve-month price target of $8.50.
• Insider trading reports indicate that major shareholders Silversmith Partners and Summit Partners sold significant shares, decreasing their positions by 20.05% each.
• LifeStance's quarterly earnings beat estimates, reporting an EPS of ($0.01) and revenues of $345.31 million, marking a year-over-year increase of 10.6%.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $8.50.

Several equities research analysts recently issued reports on LFST shares. BTIG Research started coverage on shares of LifeStance Health Group in a research note on Friday, July 25th. They set a "buy" rating and a $8.00 price target on the stock. Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, UBS Group lifted their price target on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a research note on Friday, August 8th.

Insider Transactions at LifeStance Health Group

In other news, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $18,213,249.99. Following the completion of the sale, the insider owned 14,324,197 shares of the company's stock, valued at approximately $72,623,678.79. The trade was a 20.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the sale, the insider directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,407,643 shares of company stock valued at $103,466,750. Insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its stake in LifeStance Health Group by 259.1% during the 2nd quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company's stock valued at $7,031,000 after purchasing an additional 981,349 shares during the period. Cim Investment Management Inc. raised its holdings in shares of LifeStance Health Group by 100.8% in the 2nd quarter. Cim Investment Management Inc. now owns 24,734 shares of the company's stock worth $128,000 after purchasing an additional 12,414 shares in the last quarter. State of Wyoming raised its holdings in shares of LifeStance Health Group by 31.5% in the 2nd quarter. State of Wyoming now owns 86,629 shares of the company's stock worth $448,000 after purchasing an additional 20,728 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of LifeStance Health Group by 467.4% during the second quarter. Tower Research Capital LLC TRC now owns 20,507 shares of the company's stock valued at $106,000 after acquiring an additional 16,893 shares during the period. Finally, Vident Advisory LLC raised its holdings in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company's stock valued at $112,000 after acquiring an additional 2,447 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Stock Up 1.1%

Shares of NASDAQ LFST opened at $5.41 on Thursday. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.61. The company has a market cap of $2.10 billion, a P/E ratio of -108.20 and a beta of 1.17. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average price of $4.92 and a 200 day moving average price of $5.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The firm had revenue of $345.31 million for the quarter, compared to the consensus estimate of $345.05 million. During the same quarter in the previous year, the firm posted ($0.06) EPS. The firm's quarterly revenue was up 10.6% on a year-over-year basis. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.